| Product Name | Semaglutide |
| Synonyms | Semaglutide (free base); NNC 0113-0217; NN9535; OG217SC; Sermaglutide (common misspelling) |
| CAS Number | 910463-68-2 |
| Peptide Backbone | [Aib8, Arg34]-GLP-1(7-37); 31-residue chain |
| Sequence (3-Letter) | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(acyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Side-Chain Modification | Lys26 acylated with a γ-Glu spacer, two AEEA (OEG) units, and a C18 fatty diacid (octadecanedioic acid) |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.6 |
| Category | Drug Peptide – GLP-1 receptor agonist (peptide API / reference standard) |
| Purity | ≥98% (by HPLC); pharmaceutical-grade and reference-standard specifications available |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate by default; sodium salt form available on request |
| Water Content | Per specification (Karl Fischer) |
| Related Substances | Controlled per specification; individual impurity reference standards available |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research, reference-standard, and development / API quantities) |
| QC Documentation | COA, HPLC, MS identity; extended API / regulatory documentation on request |
| Usage | For research and pharmaceutical manufacturing or analytical development use only, including as a reference standard or active pharmaceutical ingredient for licensed manufacturers. Not for human or veterinary use; not for sale to patients or individuals. Customers are responsible for regulatory and intellectual-property compliance in their territory. |
Semaglutide is a long-acting GLP-1 receptor agonist, a peptide analogue of human glucagon-like peptide-1 (GLP-1), with CAS 910463-68-2 and the molecular formula C187H291N45O59. Its backbone is a thirty-one-residue GLP-1 analogue with an Aib substitution at position eight and an arginine at position thirty-four, and a lysine side chain acylated with a spacer and a C18 fatty diacid that lets it bind albumin and act over a long duration. We make it in-house and supply it as a lyophilized powder for research and pharmaceutical manufacturing use.
Semaglutide works by binding and activating the GLP-1 receptor, a G-protein-coupled receptor. The changes to the GLP-1 sequence make it resistant to the enzyme DPP-4 and let it bind albumin, which together extend how long it stays active compared with native GLP-1. This is the pharmacology behind the approved GLP-1 medicines for type 2 diabetes and weight management. The material we supply is for research and pharmaceutical manufacturing, is not for human or veterinary use, is not for sale to patients, and we make no health, weight-loss, or therapeutic claims.
We supply Semaglutide as a synthetic peptide at high HPLC purity with a certificate of analysis, an HPLC chromatogram, and mass-spec identity confirmation. Pharmaceutical-grade and reference-standard specifications are available, including controlled related substances and extended documentation for regulatory and analytical work. Salt form, purity, and quantity can be set to your specification.
Yes. We synthesise Semaglutide in-house and supply from milligram reference and research amounts up to development and larger manufacturing batches. We also prepare related GLP-1 analogues and individual impurity reference standards to order. Send us your required grade, purity, salt form, quantity, and documentation, and we will quote it. Customers are responsible for meeting the regulatory and intellectual-property requirements that apply in their territory.
No. Semaglutide supplied by SynPeptide is a raw material for research and pharmaceutical development and manufacturing only. It is not a finished medicine, it is not for human or veterinary use, and it is not sold to patients or individuals for personal use. Any clinical or commercial medicinal use is the responsibility of an appropriately licensed party and is subject to the relevant regulatory approvals.
Semaglutide (CAS 910463-68-2) is a long-acting GLP-1 receptor agonist and one of the most widely studied peptide drug substances in metabolic medicine. It is a modified analogue of human glucagon-like peptide-1 (GLP-1) and is the active peptide behind approved GLP-1 medicines for type 2 diabetes and weight management. We supply it as a synthetic peptide for research and pharmaceutical manufacturing, including as a reference standard and active pharmaceutical ingredient for licensed development work. It is not supplied as a finished medicine and not for human use.
Semaglutide is a 31-residue GLP-1 analogue with two backbone changes from human GLP-1(7-37): an α-aminoisobutyric acid (Aib) at position 8 and an arginine at position 34. The lysine at position 26 carries a side chain built from a γ-glutamate spacer, two short AEEA (OEG) units, and a C18 fatty diacid (octadecanedioic acid). Its molecular formula is C187H291N45O59 and its molecular weight is about 4113.6. The Aib substitution blocks cleavage by the enzyme DPP-4, while the fatty-diacid side chain drives strong albumin binding; together these give the long half-life that defines the molecule.
Semaglutide is a selective agonist of the GLP-1 receptor, a G-protein-coupled receptor. Native GLP-1 is broken down within minutes by DPP-4, which makes it impractical as a drug on its own. By resisting DPP-4 and binding albumin, semaglutide stays active far longer, which is the basis for once-weekly and oral GLP-1 products. This is provided as factual background; the material we supply is for research and pharmaceutical development, not for human or veterinary use, not for sale to patients, and carries no health or therapeutic claims.
Semaglutide is a hybrid peptide: a long peptide chain plus a lipid side-chain conjugation step, which makes its manufacture and quality control demanding. As a peptide synthesis and peptide CDMO provider, we work with semaglutide as an active pharmaceutical ingredient and as a reference standard, supporting analytical method development, related-substance and impurity profiling, and process development. Individual impurity and related-substance reference standards can be prepared alongside the main compound for regulatory and stability work.
Semaglutide belongs to the GLP-1 receptor agonist class, which was built on the earlier analogue liraglutide and also includes other long-acting peptides used in metabolic research. For comparative and method-development work we can supply semaglutide together with related GLP-1 analogues, sequence variants, and labelled forms, prepared through peptide modification and held under our drug peptides range. Sourcing a compound and its impurities or analogues from the same batch keeps purity, salt form, and counter-ion consistent across a study.
Store the lyophilized peptide at -20°C, kept dry and protected from light. Because the molecule carries a fatty-acid side chain and an oxidation-sensitive tryptophan, handle it under inert gas where possible and protect it from strong oxidants. Reconstitute in a suitable aqueous buffer, aliquot stock solutions to avoid repeated freeze-thaw, and follow the certificate of analysis for lot-specific water content and storage guidance.
We make Semaglutide by solid-phase and hybrid synthesis, including the side-chain conjugation, and release it with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with grade and salt form set to your specification. Supply runs from milligram research and reference quantities through to development and larger batches, handled by our large-scale peptide synthesis and custom peptide synthesis capabilities. Material is supplied for research and pharmaceutical manufacturing use only; customers are responsible for the regulatory and intellectual-property requirements that apply in their territory.
